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Abstract 
Background :To determine the efficacy of 
Daclatasvir and Sofosbuvir plus Ribavirin in 
achieving Rapid Virological Response (RVR) in 
patients of Hepatitis C genotype 3 who are non-
cirrhotic and have not received any previous 
treatment. 
Methods: In this descriptive case series study, 100 
non cirrhotic, treatment-naïve patients of HCV 
genotype 3 were enrolled. Each patient was given 
oral tab Daclatasvir 60 mg once daily,tab Sofosbuvir 
once daily  400 mg and capsule Ribavirin 400 mg 
twice daily. HCV RNA PCR quantitative was 
obtained before treatment and repeated after 
completion of one month treatment with above 
mentioned drugs. 
Results: Mean age of included patients was 42.7 ± 
10.68 years (mean ± SD). Females were 
dominant(59%). The BMI was 26.07 ± 3.00 kg/m2. 
Out of 100 patients 87% patients achieved Rapid 
Virological Response (RVR).The data was stratified 
according to age, gender and BMI. There was no 
effect of these parameters on the final results. 
Conclusion: Rapid Virological Response (RVR) of 
Daclatasvir plus Sofosbuvir and Ribavirin is 
impressive. However, more studies are required to 
ascertain the results. 
Key Words: HCV, Genotype 3, RVR, Oral Direct 
Acting Antivirals , DAA, Daclatasvir, Sofosbuvir 
 
Introduction 
Hepatitis C is a rising and alarming global health 
problem. The hepatitis C virus  can lead to acute and 
chronic hepatitis. According to World Health 
Organization (WHO), Chronic Hepatitis C has affected 
nearly 71 million people in the world, with about 
399,000 deaths mainly due to its threatening 
complications such as  cirrhosis and hepatocellular 
carcinoma (HCC).1 Hepatitis C Virus  has 6 
homologous genotypes. Among which, HCV genotype 
3 is much common in South East Asia , as compared 
with other five known genotypes.2,3 Most common 
Genotype in Pakistan is 3a which is followed by 3b. 4  
Earlier, HCV infection was managed with interferons.  
However, these treatment regimens had low success 
rate against HCV infection, particularly against 
genotype 3, both because of their less efficacy and poor 
compliance to these regimens because of their 
adversity profile.5-7  HCV genotype 3 has been found to 
be associated with markedly increasing risk of 
developing complications like cirrhosis and 
hepatocellular carcinoma if left untreated. 8,9 
With the recent advents in treatment regimens of HCV 
infection, the therapy for HCV genotype 3 has also 
been revolutionized in recent era. Both European 
Association for the Study of the Liver. (EASL ) and 
American Association for the Study of Liver Diseases 
and the Infectious Diseases Society of America 
(AASLD) now recommend oral Direct Acting 
Antivirals (DAA) as first line treatment for HCV 
infection, owing to their efficacy and compliance .10,11 
The use of oral Direct Acting Antivirals (DAA) for 
treatment of HCV genotype 3 has been proved to be 
much efficacious in achieving Virological responses as 
compared to conventional interferons and PEG 
interferons.12 
Uptil now, the most efficacious drugs trialed against 
HCV genotype 3 are Sofosbuvir and Daclatasvir.13  
Daclatasvir (DCV)  inhibits HCV NS5A protein.14 
whereas Sofosbuvir (SOF) is an inhibitor of the HCV 
NS5B RNA polymerase.15 These proteins play basic 
part in replication of viral RNA. Although the measure 
of efficacy of these drugs has been considered to be 
able to achieve the Sustained Virological Response 
(SVR) after treatment, researchers have also focused 
on response towards therapy in terms of Rapid 
Virological response, which has been defined as 
Achievement of undetectable Hepatitis C Virus RNA 
Journal of Rawalpindi Medical College (JRMC); 2018;22(4): 306-309 
 307 
by PCR quantitative 4 weeks after initiation of 
treatment with a lower limit of detection ≤ 25 IU/ml. 
This monitoring of Rapid Virological response is 
considered to be effective in monitoring response to 
therapy.16 In one of these trials, it has been found that 
treatment of HCV genotype 3 infection with 
combination of Daclatasvir alongwith Sofosbuvir and 
Ribavirin has been reported to achieve Rapid 
Virological response (RVR) in 87% of cases in ALLY3+ 
trial.17 
Patients and Methods 
This case control study was done in Liver Clinic OPD 
of Medicine Unit II, Benazir Bhutto hospital from 01-
01-2018 to 30-06-2018 over a period of six months 
.Among the patients presenting to liver clinic, Patients 
of HCV genotype 3 who were non-cirrhotic and had 
not taken any past treatment, were enrolled in study 
after informed consent. All patients in this study had 
pre-treatment HCV RNA Quantitative levels >1000 
IU/L. Other inclusion criteria included age between 
18-70 years, and BMI >  18 kg/m2. Exclusion Criteria 
included patients who had recieved any previous 
treatment for Hepatitis C Virus infection, or patients 
who had any evidence of Cirrhosis . Pregnant women 
and patients with Hepatitis B Virus, HIV co-infection 
and decompensated liver disease were also excluded. 
All included patients were given Oral Tab Daclatasvir 
60 mg PO OD, Tab Sofosbuvir 400 mg PO Once daily, 
and Cap Ribavirin 400 mg PO twice daily as a protocol 
of treatment for HCV infection. HCV RNA PCR 
Quantitative levels were measured after completion of 
one month of treatment with these drugs to moniter 
the response to therapy and Rapid Virological 
Response (RVR) was calculated. All the categorical 
variables like gender, SVR were described as 
frequencies and percentages while for age, BMI which 
are continuous variables, mean and SD was calculated. 
Effect modifiers including age, gender, BMI were 
controlled by stratification. T-test was applied after 
stratification. p value of ≤ 0.05 was statistically 
considered significant. 
 
Results 
 100 patients were included in this study. Mean age of 
included patients was 42.70 ± 10.68 years (mean ± SD). 
The age was further distributed into two categories. 
Out of 100 patients, 59% were females and 41% were 
males. The BMI in study group was 26.07 ± 3.00 
kg/m2. Majority (87%)  achieved Rapid  Virological 
Response (RVR) (Figure 1). Data was stratified 
according to age, gender and BMI. There was no effect 
of these parameters on the final results (Table 1). 
 
 
  
Figure 1. Virological response in hepatitis C patients  
 
Table 1. RVR status after stratification 
Parameter 
RVR 
P value 
Yes No 
 Age 
<50 years 61 09 
0.949a 
>50 years 26  04 
Gender 
Male 36 05 
0.844a 
Female 51 08 
BMI 
<25 33 04 
0.622a 
>25 54 09 
 
Discussion 
Although, in few parts of the world, blood screening 
and many preventive measures have decreased the 
incidence of Hepatitis C Virus but still HCV infection 
is a considerable global health issue. The many 
genotypes of HCV, and rapid rate of mutations, have 
created difficulty in  the development of effective 
medications. The older drugs like interferons and 
ribavirin have been replaced by new oral direct acting 
antiviral agents, in which Daclatasvir and Sofosbuvir 
are considerable in treatment of Hepatitis C Virus 
genotype 3.18  
The effectiveness of new oral Direct Acting Antivirals 
is  determined by frequency of attainment of Sustained 
Virological response after treatment.  Rapid virological 
response has also been considered to be an effective 
parameter to estimate and assess the response to 
antiviral agents therapy, but its role in predicting the 
response of ongoing treatment is yet to be 
established.16 
ALLY 3+ trial done for evaluation of response of 
Daclatasvir with Sofosbuvir and Ribavirin in HCV 
genotype 3 depicted 83% of patients receiving 12  
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weeks treatment achieved RVR. Rapid Virological 
Response in our study was 87%, although our study 
did not include the cirrhotic patients as opposed to 
ALLY 3+ trial.12,13 In another study done by Goel et al, 
in 2017 a cohort of 160 patients was analyzed for RVR, 
ETR and SVR. The results showed RVR to be 91.3% in 
that cohort.19 RVR of patients was also evaluated in a 
study done by Hill A et al, which reported RVR to be 
achieved in 84% of study population .20   In a meta-
analysis done by using databases of PUBMED , 
WANFANG, CNKI, EMBASE and COCHRANE  the 
data of 1100 patients of Genotype 1 to 4 was assessed 
for achievement of virological responses after use of 
DAAs. This meta-analysis also concluded Daclastavir 
to be superior in achieving RVR and SVR . 21 
 In another meta-analysis mainly done for HCV 
genotype 1, RVR has been reported as an outcome in 
the evaluating response of DAA as an indirect 
comparison.22 Sperl J et al. reported combination of 
Sofosbuvir and Daclatasvir to be highly effective in 
patients of haemodialysis, and Saint-Laurent et al. 
reported this combination to be both efficacious and 
cost effective.23,24,   In a study , done in Italy, 
Combination therapy for HCV genotype 3 treatment 
with Daclatasvir + sofosbuvir + Ribavirin for 12 weeks 
was found more efficacious to Sofosbuvir plus 
ribavirin therapy for 6 months. Cost effectiveness of 
DCV and SOF combination therapies has also been 
established in various other studies. In our setups, 
these drugs are being rapidly introduced, however 
cost effectiveness was not evaluated. 25-27 Pakistani 
studies  suggested rate of virological responses of 
Daclastavir using combination to be above 80% in 
Pakistan. 28,29,30  Present  study is mainly focused on 
evaluation of efficacy of Daclatasvir with Sofosbuvir 
and Ribavirin in achieving Rapid Virological response. 
However patients need to be followed to determine 
End of Treatment response (ETR) and Sustained 
Virological Response (SVR) as a part of 12 week 
treatment regimen. RVR measurement during course 
of therapy can serve as useful tool to predict response 
to DAA therapy as well as it can help to evaluate the 
cases of treatment relapse during course of therapy. 
 
Conclusion 
1.The efficacy of Daclatasvir with Sofosbuvir plus 
Ribavirin in achieving Rapid Virological Response is 
impressive.  
2. It is required to ascertain efficacy of oral direct 
acting anti-virals in cirrhotic and treatment  
experienced/relapsed  patients . 
References 
1.  World Health Organization. Hepatitis C: fact sheet. 
Available at http://www.who.int/en/news-room/fact-
sheets/detail/hepatitis-c. updated october 2017. 
2.  Messina P, Humphreys I, Flaxman A, Brown A, Cooke G, 
Pybus O , et alGlobal distribution and prevalence of hepatitis 
C virus Genotypes, Hepatology.2015 Jan;61(1):77-87 
3. Smith DB, Pathirana S, Davidson F, Lawlor E, Power J. The 
origin of hepatitis C virus genotypes. J Gen Virol. 
1997;78((Pt 2)):321–28. 
4. Idrees M, Riazuddin S. Frequency distribution of hepatitis C 
virus genotypes in different geographical regions of Pakistan 
and their possible routes of transmission. BMC Infect Dis 
2008;8:69-72. 
5. Moshyk A, Martel MJ, Tahami Monfared AA, Goeree R. Cost-
effectiveness of daclatasvir plus sofosbuvir-based regimen 
for treatment of hepatitis C virus genotype 3 infection in 
Canada. J Med Econ.2016;19(2):181-92. 
6. Sarkar S, Jiang Z, Evon DM, Wahed AS, Hoofnagle JH. 
Fatigue before, during and after antiviral therapy of chronic 
hepatitis C: results from the Virahep-C study. J Hepatol.  
2012; 57(5):946-52 
7. Shahid I, AlMalki WH, Hassan S, Hafeez MH. Real-world 
challenges for hepatitis C virus medications: a critical 
overview. Crit Rev Microbiol.  2018; 44(2):143-160. 
8.  Kanwal F, Kramer JR, Ilyas J, Duan Z, El-Serag HB. HCV 
Genotype 3 is Associated with an Increased Risk of Cirrhosis 
and Hepatocellular Cancer in a National Sample of U.S. 
Veterans with HCV. Hepatology (Baltimore, Md). 
2014;60(1):98-105.  
9.  Bochud PY, Cai T, Overbeck K, Bochud M, Dufour JF. 
Genotype 3 is associated with accelerated fibrosis 
progression in chronic hepatitis C. J Hepatol 2009;51:655-
66. 
10. European Association for the Study of the Liver. EASL 
recommendations on treatment of hepatitis C 2015. J 
Hepatol 2015; 63:199-236. 
11.  American Association for the Study of Liver Diseases and the 
Infectious Diseases Society of America. Recommendations for 
testing, managing, and treating hepatitis C. 
http://www.Hcvguidelines. 2015. 
12. Welzel TM,Petersen J, Herzer K. Daclatasvir plus sofosbuvir, 
with or without ribavirin, achieved high sustained 
virological response rates in patients with HCV infection and 
advanced liver disease in a real-world cohort .Gut 
2016;65:1861–70. 
13.  Leroy V ,Angus P, Bronowiki JP, Dore GJ, Hezode C, Pianko 
S etal .Daclatasvir, Sofosbuvir, and Ribavirin for Hepatitis C 
Virus Genotype 3 and Advanced Liver Disease: A 
Randomized Phase III Study (ALLY-3+) Hepatology 
2016;63:05-09, 
14. McGivern DR, Masaki T, Williford S, Ingravallo P. Kinetic 
analyses reveal potent and early blockade of hepatitis C virus 
assembly by NS5A inhibitors. Gastroenterology. 
2014;147(453–462):457-60. 
15.  Noell BC, Besur SV, Delemos AS. Changing the face of 
hepatitis C management – the design and development of 
sofosbuvir. Drug Des Devel Ther. 2015; 9: 2367–2374. 
16.  Kowdley KV, Nelson DR, Lalezari JP, Box T. On-treatment 
HCV RNA as a predictor of sustained virological response in 
HCV genotype 3-infected patients treated with daclatasvir 
and sofosbuvir. Liver Int. 2016;36(11):1611-18. 
17.  Nelson DR, Cooper JN, Lalezari JP. All-oral 12-week 
treatment with daclatasvir plus sofosbuvir in patients with 
hepatitis C virus genotype 3 infection: ALLY-3 phase III 
study. Hepatology. 2015;61:1127–35. 
Journal of Rawalpindi Medical College (JRMC); 2018;22(4): 306-309 
 309 
18.  Pawlotsky, Michel J. NS5A inhibitors in the treatment of 
hepatitis C. Journal of Hepatology 2016;59(2): 375 -82 
19.  Goel, A., Bhargava, R., Rai, P. Treatment of chronic 
genotype-3 hepatitis C virus infection using direct-
acting antiviral agents: An Indian experience Indian J 
Gastroenterol (2017) 36: 227-30.  
20. Hill A, Khwairakpam G, Wang J. High sustained virological 
response rates using imported generic direct acting antiviral 
treatment for hepatitis C. Journal of Virus Eradication. 
2017;3(4):200-03. 
21.  Peng Q, Li K, Cao MR, Bie CQ, Tang HJ. Daclatasvir 
combined with peginterferon-α and ribavirin for the 
treatment of chronic hepatitis C: a meta-analysis. 
SpringerPlus. 2016;5(1):1569-73.  
22.  Borba HH, Wiens A, Steimbach LM. Network meta-analysis 
of first- and second-generation protease inhibitors for 
chronic hepatitis C genotype 1: efficacy based on RVR and 
SVR 24 Eur J Clin Pharmacol 2017; 73: 1-5. 
23. Sperl J, Frankova S, Kreidlova M, Merta D. Combination of 
sofosbuvir and daclatasvir in the treatment of genotype 3 
chronic hepatitis C virus infection in patients on 
maintenance hemodialysis. Ther Clin Risk Manag. 
2017;13:733-38. 
24.  Saint-Laurent Thibault C, Moorjaney D, Ganz ML. Cost-
effectiveness of combination daclatasvir-sofosbuvir for 
treatment of genotype 3 chronic hepatitis C infection in the 
United States. J Med Econ. 2017;20(7):692-702. 
25. Restelli U, Alberti A, Lazzarin A, Bonfanti M. Cost-
effectiveness analysis of the use of daclatasvir + sofosbuvir + 
ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin 
(16 weeks and 24 weeks) for the treatment of cirrhotic 
patients affected with hepatitis C virus genotype 3 . Eur J 
Health Econ. 2018;19(1):37-44. 
26.  Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C. Daclatasvir 
+ sofosbuvir versus standard of care for hepatitis C genotype 
3: a matching-adjusted indirect comparison. J Comp Eff Res. 
2016;5(2):129-39. 
27. Sundaram V, Kowdley KV. Dual daclatasvir and sofosbuvir 
for treatment of genotype 3 chronic hepatitis C virus 
infection. Expert Rev Gastroenterol Hepatol. 2016;10(1):13-
20 
28. Iqbal S, Yousuf MH, Yousaf MI. Dramatic response of 
hepatitis C patients chronically infected with hepatitis C 
virus genotype 3 to sofosbuvir-based therapies in Punjab, 
Pakistan: A prospective study. World J Gastroenterol. 
2017;23(44):7899-905. 
29.  Akhter TS, Umar M, Khaar HT, Aslam F, Nisar G. Sofosbuvir 
For The Treatment Of Hepatitis C Genotype 3 Infected 
Patients In Pakistan. J Ayub Med Coll Abbottabad. 2016;28(4 
Suppl 1):S884-S89 
30.  Sarwar S, Khan AA, Tarique S. Response guided interferon 
therapy for genotype 3 of chronic hepatitis C: Compliance 
and outcome. Pak J Med Sci 2015;31(4):843-46 
 
 
